A randomized phase 2 trial investigated low-dose interleukin-2 (IL-2) in patients with acute coronary syndrome and high C-reactive protein. Treatment with low-dose IL-2 resulted in an increase in the number of regulatory T cells compared to placebo. At the same time, a reduction in arterial (vascular) inflammation was observed in patients treated with IL-2 compared to the placebo group. Thus, the study demonstrated that the targeted influence of the immune system using a low dose of IL-2 can reduce inflammation in the arteries in this group of patients. The results were related to patients after acute coronary syndrome with increased inflammatory parameters, defined by a high level of C-reactive protein. The authors evaluated IL-2 as an anti-inflammatory intervention aimed at enhancing regulatory T cells and subsequently reducing inflammation in blood vessels. The study was published in the journal Nature Medicine as a phase 2 clinical trial.